Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases
摘要:
A series of potent, selective platelet-derived growth factor receptor-family kinase inhibitors was optimized starting from a globally selective lead molecule 4 through structural modifications aimed at improving the physiochemical and pharmacoldnetic properties, as exemplified by 18b. Further clearance reduction via per-methylation of the a-carbons of a solubilizing piperidine nitrogen resulted in advanced leads 22a and 22b. Results from a mouse tumor xenograft, a collagen-induced arthritis model, and a 7 day rat in vivo tolerability study culminated in the selection of compound 22b (AC710) as a preclinical development candidate.
acetal 6a of triacetonamine (3a) by alkylation followed by hydrolysis of the acetal functionality or alternatively from the corresponding secondary alcohol 2,2,6,6-tetramethylpiperidin-4-ol (7a) by N-alkylation and subsequent oxidation to introduce the ketone unit. Direct alkylation of 3a was only possible by using highly reactivehalides such as allyl or benzyl bromide with low yields. Treatment of
Photoreduction of Triplet Benzophenone by Tertiary Amines: Amine molecular structure and ketyl radical yield
作者:Markus Von Raumer、Paul Suppan、Edwin Haselbach
DOI:10.1002/hlca.19970800309
日期:1997.5.12
The photoreduction of triplet benzophenone by 14 tertiary amines was investigated. The ketyl radical yields do not correlate with the quenching rate constants, nor with the electron donor propensity of the amines. Individual structural features of the amines seem to determine the photoreduction yields.
The present invention relates water-soluble hindered amine compounds of the general formula (I):
wherein G
1
and G
2
are independently alkyl of 1 to 4 carbon atoms or are together pentamethylene; Z
1
and Z
2
are each methyl, or Z
1
and Z
2
together form an unsubstituted linking moiety or a linking moiety substituted by one or more groups selected from an ester, ether, hydroxy, oxo, cyanohydrin, amide, amino, carboxy or an urethane group; E is alkoxy of 1 to 18 carbon atoms, cycloalkoxy of 5 to 12 carbon atoms or aralkoxy of 7 to 15 carbon atoms, or E is —O-T-(OH)
b
; T is a straight or branched chain alkylene of 1 to 18 carbon atoms, cycloalkylene of 5 to 18 carbon atoms, cycloalkenylene of 5 to 18 carbon atoms, a straight or branched chain alkylene of 1 to 4 carbon atoms substituted by phenyl or by phenyl substituted by one or two alkyl groups of 1 to 4 carbon atoms; b is 1, 2 or 3 with the proviso that b cannot exceed the number of carbon atoms in T, and when b is 2 or 3, each hydroxyl group is attached to a different carbon atoms of T; and, HY is an inorganic or organic acid; and, wherein the total charge of cations is equal to the total charge of anions.
[EN] AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS AZOLYLE URÉE ET LEURS PROCÉDÉS D'UTILISATION
申请人:AMBIT BIOSCIENCES CORP
公开号:WO2011150198A1
公开(公告)日:2011-12-01
Provided herein are azolyl urea compounds for treatment of CSF-1R kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.